Efficacy of krill oil versus fish oil on obesity-related parameters and lipid gene expression in rats: randomized controlled study
AuthorCil, Mevra Aydin
Ghareaghaji, Atena Ghosi
Besler, Halit Tanju
MetadataShow full item record
CitationMevra Aydin Cil, Atena Ghosi Ghareaghaji, Yasin Bayir, Zehra Buyuktuncer, & Halit Tanju Besler. (2021). Efficacy of krill oil versus fish oil on obesity-related parameters and lipid gene expression in rats: randomized controlled study. PeerJ, 9, e12009. https://doi.org/10.7717/peerj.12009
Backround. This study aimed to determine the effects of LC n-3 PUFA supplementation on the prevention and treatment of obesity and obesity-related diseases, and to compare the efficiency of different LC n-3PUFAsources via biochemical and genetic mechanisms in rats. Methods. Male Wistar rats were randomized into four study groups, and fed with a standard diet, High Fat Diet (HFD), HFD+%2.5 Fish Oil (FO-HFD) or HFD+%2.5 Krill Oil (KO-HFD) for eight weeks. Food consumption, weight gain, serum glucose, insulin, ghrelin and leptin concentrations, lipid profile, liver fatty acid composition, and FADS1 and FADS2 mRNA gene expression levels were measured. Results. Weight gain in each HFD group was significantly higher than control group (p<0:001), without any differences among them (p<0:05). LC n-3 PUFAs modified lipid profile, but not glucose tolerance. Serum leptin levels were significantly higher in HFD groups than in the control group, however, no difference in serum ghrelin levels was observed among the groups. Liver n-3 fatty acid desaturation activity was higher (p D 0:74), and liver total lipid content was lower (p D 0:86) in KO-HFD compared to FO-HFD. FADS1 gene expression was highest in the HFD group (p<0:001) while FADS2 gene expression was highest in the FO-HFD group (p<0:001). Conclusion. LC n-3 PUFAs, especially krill oil, had moderate effects on lipid profile, but limited effects on obesity related parameters, suggesting different effects of different sources on gene expression levels. Further randomized controlled trials are needed to determine the efficacy of different LC n-3PUFAsources in the prevention and treatment of obesity in humans.